09.03.24 September MDL numbers increased The MDL numbers published on September 3, 2024, showed that hundreds of plaintiffs filed lawsuits against GLP-1 RA drug manufacturers
Rarely, severe side effects have been reported, such as pancreatitis, medullary thyroid cancer, acute (sudden) kidney injury, and worsening diabetes-related retinopathy
However, individual outcomes vary based on: Dose escalation Adherence Lifestyle modifications Baseline metabolic status Side Effects Profile Both medications share common GLP-1 class side effects: Nausea Vomiting Diarrhea Reduced appetite Zepbound may show slightly higher gastrointestinal intensity at higher doses due to dual receptor activity
In general, exposure by the inhalation or dermal route favours sensitization, whereas exposure by the oral route favours tolerance (unresponsiveness )
How much peptide should I inject
However, this is not an oral medication